Genetic Signatures (ASX:GSS) announced financial results for the quarter ended 30 September 2022.

Quarterly sales of $5.7 million; up 16% from preceding quarter.

Cash receipts of $7.8 million during the quarter, closing cash balance $32.4 million.

Completed recruitment for Enteric Protozoan Detection Kit pivotal clinical trial in the USA.

Independent study reporting high detection rate for Antimicrobial Resistance Detection Kit.

New sites in Australia including two pathology laboratories in Western Australia.

Health Canada licenses EasyScree Enteric Protozoan Detection Kit.

Following the announcement the company?s share price rose 4.999%.